Immunic
Yahoo Finance • 2 years ago
After Positive Data In Ulcerative Colitis Study, Immunic Prioritizes Vidofludimus Calcium Program With One More Candidate
Immunic, Inc (NASDAQ: IMUX) reported data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset, vidofludimus calcium (IMU-838), in patients with moderate-to-severe ulcerative colitis (UC). Data showed a dose-linear incr... Full story
Yahoo Finance • 2 years ago
Immunic, Inc. (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript
Immunic, Inc. (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript February 23, 2023 Jessica Breu: Good morning and welcome to Immunic's Fourth Quarter and Year End 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Com... Full story
Yahoo Finance • 2 years ago
Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update
– Initial Results From Ongoing Part C of Phase 1 Clinical Trial of IMU-856 in Celiac Disease Expected Mid-2023 – – Interim Results From Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in the Secon... Full story
Yahoo Finance • 2 years ago
Companies Like Immunic (NASDAQ:IMUX) Could Be Quite Risky
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune... Full story
